

Hans-Hennig Flechtner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/946664/publications.pdf>

Version: 2024-02-01

82
papers

16,012
citations

101543

36
h-index

39675

94
g-index

105
all docs

105
docs citations

105
times ranked

16800
citing authors

#	ARTICLE	IF	CITATIONS
1	Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials. Lung Cancer, 2022, 167, 65-72.	2.0	6
2	Randomized Trial of a Supportive Psychotherapy for Parents of Adolescents and Young Adults With Hematologic Malignancies. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, , 1-15.	4.9	4
3	Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study. European Journal of Cancer, 2022, 170, 1-9.	2.8	6
4	Effects of a five-day HD-tDCS application to the right IFG depend on current intensity: A study in children and adolescents with ADHD. Progress in Brain Research, 2021, 264, 117-150.	1.4	10
5	Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. Neuro-Oncology, 2021, 23, 1327-1336.	1.2	15
6	Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors. European Journal of Haematology, 2021, 106, 697-707.	2.2	1
7	Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials. BMC Cancer, 2021, 21, 1083.	2.6	12
8	Effects of long-term psychodynamic psychotherapy on life quality in mentally disturbed children. Psychotherapy Research, 2020, 30, 1039-1047.	1.8	6
9	Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy. Colorectal Disease, 2020, 22, 2278-2287.	1.4	22
10	Hodgkin lymphoma. Nature Reviews Disease Primers, 2020, 6, 61.	30.5	103
11	Economical Assessment of Working Memory and Response Inhibition in ADHD Using a Combined n-back/Nogo Paradigm: An ERP Study. Frontiers in Human Neuroscience, 2020, 14, 322.	2.0	7
12	Exploration of a novel virtual environment improves memory consolidation in ADHD. Scientific Reports, 2020, 10, 21453.	3.3	15
13	Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer. Gynecologic Oncology, 2020, 159, 515-521.	1.4	12
14	Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group. Journal of Clinical Oncology, 2020, 38, 2839-2848.	1.6	28
15	Comparison between conventional and HD-tDCS of the right inferior frontal gyrus in children and adolescents with ADHD. Clinical Neurophysiology, 2020, 131, 1146-1154.	1.5	42
16	International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. Lancet Oncology, The, 2020, 21, e83-e96.	10.7	180
17	Quality of Life in Hodgkin Lymphoma. Hematologic Malignancies, 2020, , 419-427.	0.2	0
18	Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer. JNCI Cancer Spectrum, 2019, 3, pkz037.	2.9	46

#	ARTICLE	IF	CITATIONS
19	Current state of quality of life and patient-reported outcomes research. <i>European Journal of Cancer</i> , 2019, 121, 55-63.	2.8	83
20	Sensitivity to change of the EORTC quality of life module measuring cancer-related fatigue (EORTC Tj ETQq0 0 0,rgBT /Overlock 10 Tf	2.3	19
21	Regional Gray Matter Volume Differences Between Adolescents With ADHD and Typically Developing Controls: Further Evidence for Anterior Cingulate Involvement. <i>Journal of Attention Disorders</i> , 2018, 22, 627-638.	2.6	41
22	Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol. <i>BMJ Open</i> , 2018, 8, e019117.	1.9	45
23	Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma. <i>European Journal of Cancer</i> , 2018, 104, 169-181.	2.8	38
24	Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. <i>Lancet Oncology</i> , The, 2018, 19, e459-e469.	10.7	66
25	Orbitofrontal Signaling of Future Reward is Associated with Hyperactivity in Attention-Deficit/Hyperactivity Disorder. <i>Journal of Neuroscience</i> , 2018, 38, 6779-6786.	3.6	22
26	Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. <i>Clinical Trials</i> , 2018, 15, 624-630.	1.6	42
27	Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials. <i>Cancer</i> , 2018, 124, 3409-3416.	4.1	60
28	Measuring family functioning in families with parental cancer: Reliability and validity of the German adaptation of the Family Assessment Device (FAD). <i>Journal of Psychosomatic Research</i> , 2017, 93, 110-117.	2.6	14
29	International Psychometric Validation of an EORTC Quality of Life Module Measuring Cancer Related Fatigue (EORTC QLQ-FA12). <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	115
30	Improving Interference Control in ADHD Patients with Transcranial Direct Current Stimulation (tDCS). <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 72.	3.7	66
31	Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration. <i>Journal of Clinical Oncology</i> , 2016, 34, 4329-4337.	1.6	70
32	PRO-ONKOâ€”selection of patient-reported outcome assessments for the clinical use in cancer patientsâ€”a mixed-method multicenter cross-sectional exploratory study. <i>Supportive Care in Cancer</i> , 2016, 24, 2503-2512.	2.2	11
33	Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. <i>Lancet Oncology</i> , The, 2016, 17, 1453-1462.	10.7	91
34	Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. <i>Lancet Oncology</i> , The, 2016, 17, e510-e514.	10.7	158
35	Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours. <i>European Urology</i> , 2016, 69, 518-525.	1.9	12
36	The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv391.	6.3	28

#	ARTICLE	IF	CITATIONS
37	The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. <i>European Journal of Cancer</i> , 2015, 51, 2808-2819.	2.8	105
38	Altered salience processing in attention deficit hyperactivity disorder. <i>Human Brain Mapping</i> , 2015, 36, 2049-2060.	3.6	28
39	Task-Irrelevant Novel Sounds Improve Attentional Performance in Children With and Without ADHD. <i>Frontiers in Psychology</i> , 2015, 6, 1970.	2.1	8
40	Quality of Life in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2015, , 365-374.	0.2	2
41	A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. <i>Cancer</i> , 2014, 120, 302-311.	4.1	168
42	Quality of life in long-term survivors following treatment for Hodgkin's disease during childhood and adolescence in the German multicentre studies between 1978 and 2002. <i>Supportive Care in Cancer</i> , 2014, 22, 1519-1529.	2.2	45
43	Children of cancer patients: Prevalence and predictors of emotional and behavioral problems. <i>Cancer</i> , 2014, 120, 2361-2370.	4.1	44
44	Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial. <i>British Journal of Cancer</i> , 2014, 110, 2427-2433.	6.4	74
45	Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials. <i>Lancet Oncology</i> , The, 2014, 15, e78-e89.	10.7	39
46	Has health-related quality-of-life assessment in EORTC clinical trials helped to obtain regulatory approvals and change clinical practice? A review of the EORTC experience in cancer clinical trials.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9570-9570.	1.6	0
47	Chemotherapy compared to surgery: Quality-of-life analysis of the German prospective multicenter trial in clinical stage I NSGCT (AUO AH 01/94).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4563-4563.	1.6	0
48	Psychological distress in cancer patients with underage children: gender-specific differences. <i>Psycho-Oncology</i> , 2013, 22, 823-828.	2.3	39
49	Development of an EORTC quality of life phase III module measuring cancer-related fatigue (EORTC) Tj ETQq1 1 0,784314 rgBT /Over 2,3 61	2.3	61
50	Coping skills and mental health status in adolescents when a parent has cancer: A multicenter and multi-perspective study. <i>Journal of Psychosomatic Research</i> , 2013, 74, 252-259.	2.6	57
51	Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group. <i>British Journal of Cancer</i> , 2013, 108, 49-57.	6.4	34
52	Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients. <i>Annals of Oncology</i> , 2013, 24, 231-237.	1.2	12
53	When a parent has cancer: challenges to patients, their families and health providers. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 795-808.	1.4	35
54	Parental palliative cancer: psychosocial adjustment and health-related quality of life in adolescents participating in a German family counselling service. <i>BMC Palliative Care</i> , 2012, 11, 21.	1.8	24

#	ARTICLE	IF	CITATIONS
55	Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. <i>Supportive Care in Cancer</i> , 2011, 19, 1753-1760.	2.2	133
56	Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 587-599.	1.4	12
57	Patient Self-Reports of Symptoms and Clinician Ratings as Predictors of Overall Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1851-1858.	6.3	196
58	Altered evoked gamma-band responses reveal impaired early visual processing in ADHD children. <i>Neuropsychologia</i> , 2010, 48, 1985-1993.	1.6	40
59	Epoetin Alfa in Patients With Advanced-Stage Hodgkin's Lymphoma: Results of the Randomized Placebo-Controlled GHSG HD15EPO Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 2239-2245.	1.6	54
60	Increased Echogenicity of the Substantia Nigra in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>Biological Psychiatry</i> , 2010, 68, 352-358.	1.3	27
61	PCN127 MINIMAL CLINICALLY MEANINGFUL DIFFERENCES FOR THE EORTC QLQ-C30 AND EORTC QLQ-BN20 SCALES IN BRAIN CANCER PATIENTS. <i>Value in Health</i> , 2010, 13, A275-A276.	0.3	0
62	Making better use of existing cancer data: Patient Reported Outcomes and Behavioural Evidence: a new international initiative. <i>European Journal of Cancer Care</i> , 2009, 18, 105-107.	1.5	8
63	Validation of the Hypomania Checklist (HCL-32) in a nonclinical sample of German adolescents. <i>Journal of Adolescence</i> , 2009, 32, 1075-1088.	2.4	41
64	Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. <i>Lancet Oncology</i> , The, 2009, 10, 1160-1170.	10.7	96
65	Variability and Sample Size Requirements for Health-Related Quality-of-Life Measures: Understanding the Challenges Facing Investigators. <i>Journal of Clinical Oncology</i> , 2005, 23, 8541-8542.	1.6	2
66	925: Risk-Adapted Treatment is Not Superior to Surgery – A Quality of Life Analysis of the German Prospective Multicenter Trial in Clinical Stage I NSGCT. <i>Journal of Urology</i> , 2004, 171, 245-246.	0.4	0
67	Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy – results of a randomized trial. <i>Annals of Hematology</i> , 2003, 82, 469-475.	1.8	16
68	Beyond the Development of Health-Related Quality-of-Life (HRQOL) Measures: A Checklist for Evaluating HRQOL Outcomes in Cancer Clinical Trials – Does HRQOL Evaluation in Prostate Cancer Research Inform Clinical Decision Making?. <i>Journal of Clinical Oncology</i> , 2003, 21, 3502-3511.	1.6	230
69	Fatigue and Quality of Life: Lessons from the Real World. <i>Oncologist</i> , 2003, 8, 5-9.	3.7	234
70	Guidelines for the Use of Epoetin: Have Quality-of-Life Benefits Been Proven?. <i>Journal of Clinical Oncology</i> , 2003, 21, 2223-2223.	1.6	5
71	Model-Based Methodology for Analyzing Incomplete Quality-of-Life Data and Integrating Them into the Q-Twist Framework. <i>Medical Decision Making</i> , 2003, 23, 54-66.	2.4	12
72	Fatigue assessment in cancer clinical trials. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2002, 2, 67-76.	1.4	15

#	ARTICLE	IF	CITATIONS
73	Quality of life in oncology clinical trials: present and future challenges. Expert Review of Pharmacoeconomics and Outcomes Research, 2002, 2, 84-86.	1.4	1
74	Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?. Lancet Oncology, The, 2002, 3, 145-153.	10.7	51
75	Erythropoietin improves quality of life—a response. Lancet Oncology, The, 2002, 3, 527.	10.7	3
76	RPLND or Primary Chemotherapy in Clinical Stage IIA/B Nonseminomatous Germ Cell Tumors?. European Urology, 2000, 37, 582-594.	1.9	114
77	The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. Journal of the National Cancer Institute, 1993, 85, 365-376.	6.3	12,309
78	Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients.. Journal of Clinical Oncology, 1991, 9, 614-624.	1.6	51
79	Sequential High Dose Methotrexate, 5-Fluorouracil and Folinic Acid Does Not Improve Response Rates in Advanced Colorectal Cancer. Oncology Research and Treatment, 1989, 12, 161-163.	1.2	2
80	5-Fluorouracil, 4-Epidoxorubicin, and Mitomycin C (FEM) Combination Chemotherapy for Advanced Gastric Carcinoma. A Phase-II Trial by the “Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)“ Oncology Research and Treatment, 1987, 10, 67-71.	1.2	6
81	Chemotherapy of Advanced Gastric Carcinoma. Oncology Research and Treatment, 1986, 9, 319-331.	1.2	6
82	Neural Mechanisms Underlying the Effects of Novel Sounds on Task Performance in Children With and Without ADHD. Frontiers in Human Neuroscience, 0, 16, .	2.0	1